Results 311 to 320 of about 4,600,401 (406)

How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC

European Journal of Heart Failure, EarlyView.
Linking guideline‐directed medical therapy (GDMT) implementation and appropriate polypharmacy management in heart failure (HF). Polypharmacy can represent a barrier to the proper implementation of life‐prolonging GDMT for HF. A reasonable balance between the optimization of GDMT and avoiding inappropriate polypharmacy is mandatory in the contemporary ...
Davide Stolfo, Massimo Iacoviello, Ovidiu Chioncel, Markus S. Anker, Antoni Bayes‐Genis, Frieder Braunschweig, Antonio Cannata, Seif El Hadidi, Gerasimos Filippatos, Pardeep Jhund, Alexandre Mebazaa, Brenda Moura, Massimo Piepoli, Robin Ray, Arsen D. Ristic, Petar Seferovic, Maggie Simpson, Hadi Skouri, Carlo Gabriele Tocchetti, Sophie Van Linthout, Cristiana Vitale, Maurizio Volterrani, Kalliopi Keramida, Sven Wassmann, Basil S. Lewis, Marco Metra, Giuseppe M.C. Rosano, Gianluigi Savarese   +27 more
wiley   +1 more source

Recurrent Acute Myocardial Infarction in a Patient with Severe Coronary Artery Ectasia Followed Up for 10 Years: Implications of Anticoagulant Therapy. [PDF]

Am J Case Rep
Liang M, Sun P, Li Y.
europepmc   +1 more source

Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure

European Journal of Heart Failure, EarlyView.
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata, Kotaro Nochioka, Satoshi Yasuda, Koichi Ishida, Takashi Shiroto, Jun Takahashi, Shintaro Kasahara, Ruri Abe, Shinsuke Yamanaka, Takahide Fujihashi, Hideka Hayashi, Shintaro Kato, Katsunori Horii, Kanako Teramoto, Tsutomu Tomita, Satoshi Miyata, Koichiro Sugimura, Iwao Waga, Masao Nagasaki, Hiroaki Shimokawa   +19 more
wiley   +1 more source

Factor XI and XIa inhibition: a new approach to anticoagulant therapy. [PDF]

Br J Cardiol
Sammut MA, Elamin N, Storey RF.
europepmc   +1 more source

The effect of pharmacist-led interventions on the appropriateness and clinical outcomes of anticoagulant therapy: a systematic review and meta-analysis. [PDF]

Eur Heart J Qual Care Clin Outcomes
Kefale B, Peterson GM, Mirkazemi C, Bezabhe WM.   +3 more
europepmc   +1 more source

Patients’ Preferences in Anticoagulant Therapy: Discrete Choice Experiment

Circulation. Cardiovascular Quality and Outcomes, 2014
M. Najafzadeh, J. Gagne, N. Choudhry, J. Polinski, J. Avorn, S. Schneeweiss   +5 more
semanticscholar   +1 more source

Engineered Exosome‐Based Senolytic Therapy Alleviates Stroke by Targeting p21+CD86+ Microglia

Exploration, EarlyView.
We identified a harmful immune cell type, p21+CD86+ microglia, driving post‐stroke inflammation and developed a targeted exosome‐based therapy (Que@micro‐Exo) to eliminate these cells. This innovative treatment reduced inflammation, alleviated brain damage, and improved recovery in stroke models, offering a promising strategy for stroke and other ...
Jialei Yang, Shipo Wu, Miao He
wiley   +1 more source

Spinal subdural hematoma with sudden onset of paraplegia in a patient on oral anticoagulant therapy. [PDF]

Clin Case Rep
Ito H, Hirata H, Yoshihara T, Tsukamoto M, Watanabe K, Egashira Y, Mawatari M, Morimoto T.   +7 more
europepmc   +1 more source

Anticoagulant Therapy during Noncardiac Perioperative Period for Patients with Mechanical Heart Valve Prosthesis.

, 1995
Motoyo Iwade, Miwako Kawamata, Minoru Nomura, Hidehiro Suzuki, Kazunori Iwade, M Aosaki   +5 more
openalex   +2 more sources

Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study

International Journal of Cancer, EarlyView.
What's New? Current treatment goals for polycythemia vera, a myeloproliferative neoplasm characterized by JAK2 mutations, are mainly to prevent thrombosis. While ropeginterferon alfa‐2b treatment also reduces JAK2 mutation burden, the correlation between the hematologic and molecular responses remains to be clarified.
Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, Gyeong‐Won Lee, Sang Kyun Sohn, Ho‐Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun‐Ji Choi, June‐Won Cheong, Soo‐Mee Bang, Joon Seong Park, Suk Joong Oh, Yong Park, Young Hoon Park, Sung‐Eun Lee   +15 more
wiley   +1 more source